eMedicine Specialties > Dermatology > Malignant Neoplasms

Erythroplasia of Queyrat (Bowen Disease of the Glans Penis): Follow-up

Author: Joseph L Wilde, MD, Mohs Micrographic Surgery, Chief, Department of Dermatology, Brooke Army Medical Center
Contributor Information and Disclosures

Updated: Jan 15, 2008

Follow-up

Further Outpatient Care

Close follow-up monitoring is required for patients treated medically or surgically for EQ. Local recurrence rates range from 3-10%.

Deterrence/Prevention

Uncircumcised men are at greatest risk of developing EQ; however, adult circumcision has not proven to decrease the risk. Concomitant chronic inflammatory dermatoses of the penis also can increase the potential for developing EQ.

All transplantation patients or any patients on immunosuppressive medications should undergo a thorough cutaneous examination to include genital skin as part of the initial workup and any subsequent visits.

Effective treatment and minimization of the inflammation from any infectious or inflammatory process is important.

Prognosis

Early diagnosis and treatment provide patients with an excellent chance of cure. Most studies show the cure rate to be greater than 90%.

Patient Education

Instruct patients concerning personal hygiene and the importance of cleansing beneath the foreskin to minimize the irritant effects of urine and smegma. Additionally, emphasize the importance of preventing sexually transmitted diseases such as genital herpes, human papillomavirus, and bacterial infections.

For excellent patient education resources, visit eMedicine's Men's Health Center and Cancer and Tumors Center. Also, see eMedicine's patient education article Cancer: What You Need to Know.

Miscellaneous

Medicolegal Pitfalls

Failure to carefully evaluate any patient, especially uncircumcised patients, presenting with a subacute or chronic balanitis. The threshold for performing skin biopsy of any lesion should be very low.10 In addition, failure to diagnose EQ expediently can easily result in disease that progresses to frank squamous cell carcinoma of the penis.

 


More on Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)

Overview: Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)
Differential Diagnoses & Workup: Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)
Treatment & Medication: Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)
Follow-up: Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)
Multimedia: Erythroplasia of Queyrat (Bowen Disease of the Glans Penis)
References
[ CLOSE WINDOW ]

References

  1. Goette DK. Review of erythroplasia of Queyrat and its treatment. Urology. Oct 1976;8(4):311-5. [Medline].

  2. Davis-Daneshfar A, Trüeb RM. Bowen's disease of the glans penis (erythroplasia of Queyrat) in plasma cell balanitis. Cutis. Jun 2000;65(6):395-8. [Medline].

  3. Arlette JP. Treatment of Bowen's disease and erythroplasia of Queyrat. Br J Dermatol. Nov 2003;149 Suppl 66:43-9. [Medline].

  4. Harrington KJ, Price PM, Fry L, Witherow RO. Erythroplasia of Queyrat treated with isotretinoin. Lancet. Oct 16 1993;342(8877):994-5. [Medline].

  5. Orengo I, Rosen T, Guill CK. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol. Oct 2002;47(4 Suppl):S225-8. [Medline].

  6. Micali G, Nasca MR, De Pasquale R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol. Nov 2006;55(5):901-3. [Medline].

  7. Lee MR, Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas J Dermatol. Aug 2005;46(3):196-8. [Medline].

  8. Brown MD, Zachary CB, Grekin RC, Swanson NA. Genital tumors: their management by micrographic surgery. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):115-22. [Medline].

  9. Conejo-Mir JS, Muñoz MA, Linares M, Rodríguez L, Serrano A. Carbon dioxide laser treatment of erythroplasia of Queyrat: a revisited treatment to this condition. J Eur Acad Dermatol Venereol. Sep 2005;19(5):643-4. [Medline].

  10. Gerber GS. Carcinoma in situ of the penis. J Urol. Apr 1994;151(4):829-33. [Medline].

  11. Graham JH, Helwig EB. Erythroplasia of Queyrat. A clinicopathologic and histochemical study. Cancer. Dec 1973;32(6):1396-414. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

carcinoma in situ of the penis, Bowen disease, penile carcinoma, penile neoplasia, EQ, erythroplasia of the glans penis, uncircumcised men, erythematous plaques, penile Bowen disease, papillomavirus-induced carcinoma in situ

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Joseph L Wilde, MD, Mohs Micrographic Surgery, Chief, Department of Dermatology, Brooke Army Medical Center
Joseph L Wilde, MD is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology
Disclosure: Nothing to disclose.

Medical Editor

Mark W Cobb, MD, Consulting Staff, WNC Dermatological Associates
Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Society of Dermatopathology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Mary Farley, MD, Dermatologic Surgeon/Mohs Surgeon, Department of Dermatology, The Skin Surgery Center
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

RELATED EMEDICINE ARTICLES
Patient Education
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.